D933IC00001

Research code: D933IC00001
Research name: An open-label, multicentre phase 1b study evaluating the efficacy and safety of durvalumab in combination with new oncology therapies, with or without chemotherapy in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) (MAGELLAN).
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD